Annovis Bio, Inc. (ANVS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-02. ClinicalTrials.gov
Short Interest
Short interest: 13.99% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
- Annovis to Host Corporate Update Webinar on September 2, 2026
- The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
- Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
- Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
- Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
- Annovis Bio Regains NYSE Listing Compliance
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Annovis Bio, Inc..
Full ANVS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.